Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ro 12-7310 is a synthetic retinoid compound, also known as demethyletretin. It is structurally related to other retinoids and has been studied primarily as an experimental drug. Ro 12-7310 acts by inhibiting the release of arachidonic acid, which may impact inflammatory pathways[2][9]. It binds with high affinity to cellular retinoic acid binding proteins (CRABPs), suggesting it mimics or modulates endogenous retinoid signaling in cells[5]. Retinoids are known for their roles in regulating cell growth, differentiation, and keratinocyte biology; thus, Ro 12-7310 has been investigated for its effects on keratinocyte differentiation and potential dermatological applications[10]. The compound remains experimental and is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ro 12-7310.